Skip to main content
Premium Trial:

Request an Annual Quote

Cellzome Raises 30 Million Euro in Series C

NEW YORK, March 18 - Cellzome has raised 30 million euro ($31.9 million) in a Series C financing, the company said today.

 

The Heidelberg, Germanyproteomics company will use the funds for R&D  and proof-of-concept studies for its drug discovery process, which involves matching proteins to disease pathways and existing medicinal chemistry.

 

Invesco Private Capital led the financing round, and was joined by new investors Biofrontier Partners, SG Asset Management, and Yamanouchi Venture Capital; and prior investors Advent International, Atlas Venture, Index Ventures, Heidelberg Innovation, Schroder Ventures Life Sciences, Sofinnova Partners, and Stelios Papadopoulos.

 

 

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.